AXDX - Accelerate Diagnostics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Accelerate Diagnostics, Inc.

3950 South Country Club Road
Suite 470 4th Floor
Tucson, AZ 85714
United States

IndustryDiagnostics & Research
Full Time Employees287

Key Executives

NameTitlePayExercisedYear Born
Mr. Lawrence MehrenPres, CEO, Director and Interim Head of Europe, Middle East & Africa375kN/A1966
Mr. Steve ReichlingChief Financial Officer240kN/A1978
Mr. Ron PriceSr. VP & Head of Commercial Operations - Americas240kN/A1964
Mr. Jack PhillipsChief Operating OfficerN/AN/AN/A
Dr. Romney M. HumphriesChief Scientific OfficerN/AN/A1981
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.

Corporate Governance

Accelerate Diagnostics, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 4. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 1; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.